#Camer_A_pril #Dag2 van @jolanda.bsky.social
#thema : #Patroon #Pattern
#tekening #inkt gemaakt toen ik 12 jaar was #inspiratie #Zadkine's #manzonderhart #stadzonderhart #Rotterdam

MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference MiNK Therapeutics (NASDAQ: INKT) announced an abstract acceptance for presentation at the American Thoracic Society (ATS) 2026 International Conference in Orlando, May 15-20, 2026. The abstract describes a combination of N-803 and investigational agenT-797 for unresolving Coccidioides immitis infection.Presenter Terese Hammond, MD, will present Poster Board #103 in Session D107 on Wednesday, May 20, 2026, 11:00 AM–1:00 PM EDT. In line with ATS rules, no data or results are disclosed until the conference presentation.

#INKT MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

www.stocktitan.net/news/INKT/mi-nk-therapeu...

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum MiNK Therapeutics (NASDAQ: INKT) reported Q4 and full‑year 2025 results and highlighted multiple 2026 clinical catalysts. Key facts: cash $13.4M at year‑end, an additional $3.0M raised post‑year, net loss $12.5M for FY2025, and advancing Phase 2 ARDS and GVHD programs with near‑term readouts.Non‑dilutive funding includes a $1.1M C‑Further collaboration, an NIH NIAID STTR grant, and the Mary Gooze award, supporting clinical starts in 1H–2H 2026.

#INKT MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

www.stocktitan.net/news/INKT/mi-nk-therapeu...

📢 Stocks Trending NOW: #NIO #ORCL #KSS #JOBY #BNTX #GSIW #RIVN #INKT #VTAK #CRSP

MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers MiNK Therapeutics (Nasdaq: INKT) announced a strategic collaboration with C-Further to develop a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers.The program receives up to ~$1.1 million in non-dilutive, aggregate funding for IND-enabling work and milestone-driven preclinical candidate nomination, plus a meaningful double-digit share of downstream commercial revenues; collaboration is non-exclusive.

#INKT MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

www.stocktitan.net/news/INKT/mi-nk-therapeu...

Meet the CiRT 2026 meeting speakers: Dr. Bruce Levine, a pioneer of modern cell and gene therapy.

Read more and register! meeting2026.cirt-net.org/registration/
#inkt #research #consortium #cirt

Gekleurde tattoo-inkt veroorzaakt heftige allergische reactie en blijvende gezondheidsproblemen bij Poolse man In het kort Een 36-jarige man uit Polen kreeg een reeks ongewone symptomen na het zetten van een veelkleurige tattoo. Aanvankelijk had hij last van hevige jeuk en een wijdverspreide rode uitslag. Na verloop van tijd verergerden deze symptomen, wat leidde tot haaruitval, gele nagels, gezwollen lymfeklieren en het uitblijven van transpiratie. Na twee jaar […] The post Gekleurde tattoo-inkt veroorzaakt heftige allergische reactie en blijvende gezondheidsproblemen bij Poolse man appeared first on Newsmonkey.

Gekleurde tattoo-inkt veroorzaakt heftige allergische reactie en blijvende gezondheidsproblemen bij Poolse man #tattoo #allergie #gezondheid #inkt #kleurentattoo

AgenT-797 (iNKT): Uses in Cancer, Side Effects, Dosages, Expectations, and Clinical Trial Evidence - OncoDaily AgenT-797 is an investigational invariant NKT cell therapy for relapsed cancers, with early trials showing immune activation and a favorable safety profile.

AgenT-797 (iNKT): Uses in Cancer, Side Effects, Dosages, Expectations, and Clinical Trial Evidence

oncodaily.com/drugs/agent-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #iNKT #AgenT-797

Most Searched, Thursday December 4, 2025 – Crystal Equity Research

Most searched small-cap stocks, Thu Dec 4th - #PLRZ #BTBT #IRBT #PMI #DNN #SERV #RR #QCLS #PLUG #BBAI #SMX #SG #SBET #SANA #QUBT #ONDS #LAC #INKT #CMCL #USAR - More: crystalequityresearch.com/most-searche... - #smallcap

#modeldrawing #modeltekenen #live #sketching which way to continue? Picture 1 are small #drawings with #inkt and #watercolour & picture 2 is on a larger format and with #oil pastels?
#artschool

#inkt #week49

Linea tinctura #archive #soundtrack #paradiseranche #art #inkt #ink #markschneiders #paper #scribbles

MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors MiNK Therapeutics (NASDAQ: INKT) on November 20, 2025 published preclinical data for MiNK-215, an allogeneic, IL-15–enhanced FAP-targeting CAR-iNKT designed to remove FAP+ cancer-associated fibroblasts and boost immune infiltration in solid tumors.Key preclinical findings show MiNK-215: dismantles stromal barriers, selectively eliminates FAP+ fibroblasts, remodels the tumor microenvironment, activates dendritic cell and antigen-presentation pathways, repolarizes macrophages to a pro-inflammatory state, and enables deep tumor-specific T cell infiltration in refractory lung and MSS colorectal cancer models.MiNK-215 is described as an off-the-shelf therapy manufacturable at scale to address solid tumors resistant to checkpoint inhibitors.

#INKT MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

www.stocktitan.net/news/INKT/mi-nk-therapeu...

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation MiNK Therapeutics (NASDAQ: INKT) reported Q3 2025 results and clinical progress on its allogeneic iNKT platform. Key clinical highlights include durable responses with agenT-797 in checkpoint- and chemotherapy-refractory solid tumors, including complete remissions >2 years and multi-year survivors, with no ≥Grade 3 CRS or neurotoxicity reported.The company launched an NIH- and philanthropically funded GvHD collaboration with UW–Madison and plans a Phase 2+ severe pulmonary disease trial using FDA-validated endpoints. Leadership additions target pulmonary, trauma, and biodefense expertise. Cash was $14.3M at 9/30/25 (plus $1.2M subsequent raise), providing runway through 2026.

#INKT MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

www.stocktitan.net/news/INKT/mi-nk-therapeu...

#INKT MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

www.stocktitan.net/news/INKT/mi-nk-therapeu...

Inkt drawing text We the People and the shadow of WE reads as ME. Everything except ME is splotched. Caption text: The state of the 'Greatest democracy' on earth

#inktober2025 #inktober #inkt #day4 #murky

Geupdate schets van mijn voorplaatsillustratie met de karakters van mijn strips "Antarctica - on the rocks" en "de school van Ariplates" nu aangevuld met karakters uit "Peer de plintkabouter", "Ambrosius" en "Paling & Ko"

Inkt versie van mijn voorplaatsillustratie met de karakters van mijn strips "Antarctica - on the rocks" en "de school van Ariplates" aangevuld met karakters uit "Peer de plintkabouter", "Ambrosius" en "Paling & Ko"

"platte" kleurversie van mijn voorplaatsillustratie met de karakters van mijn strips "Antarctica - on the rocks" en "de school van Ariplates" aangevuld met karakters uit "Peer de plintkabouter", "Ambrosius" en "Paling & Ko"

Mockup versie van mijn voorplaatsillustratie met de karakters van mijn strips "Antarctica - on the rocks" en "de school van Ariplates" aangevuld met karakters uit "Peer de plintkabouter", "Ambrosius" en "Paling & Ko"

Mijn uitgever vroeg om nog wat extra karakters toe te voegen die in het magazine voorkomen. Dat leverde het volgende resultaat op.
#WIP
#SCHETS
#INKT
#INKLEURING
#MOCKUP
#ART
#STRIP
#comic
#stripmagazine

Leading Indicators, Thursday September 25, 2025 – Crystal Equity Research

Small-cap stocks with declining money flow, Thu Sept 25th - #MTNB #DSS #ZYXI #UNIT #TRUE #SCVL #PGEN #OSS #NBN #INKT #DYN #CAC #BASE #ACB #USNA #SFL #PHR #NLOP #LUXE #HE #BAK #ACCO - More: crystalequityresearch.com/leading-indi... - #smallcap

First-in-Human Results: MiNK's Off-the-Shelf Cell Therapy Shows Disease Reversal in Immune Disorders MiNK Therapeutics CEO Dr. Jennifer Buell to present breakthrough iNKT cell therapy data showing durable disease reversal in immune disorders at 10th Annual CAR-TCR Summit in Boston.

#INKT MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

www.stocktitan.net/news/INKT/mi-nk-therapeu...

Welcome to our 2 new lab members--Margaret Bohm and Bibiana Barrios!! Also want to recognize all of Emily Landy's hard work! #NationalPostdocAppreciationWeek
#iNKT #iNKTcells #GVHD #CellTherapy #immunology #GVHDsm #bmtsm @washumedicine.bsky.social @sitemancenter.bsky.social

Deze gedetailleerde regenbui werd door Frauke aandachtig geschilderd met verdunde inkt. Met teken- en schilderles ben je de hele herfst en winter onder de pannen!
Ons atelier in Amsterdam verwelkomt beginners en gevorderden: www.groetenvanmarc.nl
#tekenles #schilderles #regenbui #water #inkt

JUST IN: ( NASDAQ: #INKT ) Expected US Company Earnings on Thursday, August 14th, 2025

JUST IN: ( NASDAQ: #INKT ) Expected earnings - MiNK Therapeutics Inc.

MiNK Therapeutics Cuts Q2 Cash Use 31% | The Motley Fool

#INKT #80cecece-6ae8-4dbc-85c8-f217624364bc #data-news

Origin | Interest | Match

Cancer Breakthrough: MiNK's Cell Therapy Achieves Complete Remission in Metastatic Testicular Cancer Novel iNKT cell therapy delivers complete remission in treatment-resistant testicular cancer. Company raises $13M to extend runway through 2026. New DOD grant advances GvHD program. Learn more.

#INKT MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

www.stocktitan.net/news/INKT/mi-nk-therapeu...

CAR T-Cell Therapy vs iNKT Cell Therapy: The Future of Engineered Immune Cells in Cancer Treatment - OncoDaily CAR T-cell therapy vs iNKT cell therapy: Explore 2025 data on efficacy, safety, and future directions in cancer immunotherapy.

CAR T-Cell Therapy vs iNKT Cell Therapy: The Future of Engineered Immune Cells in Cancer Treatment

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CART #iNKT #ImmuneCells #IO #Immunotherapy

Eigenlijk neem ik geen opdrachten aan. Maar soms, heel soms, maak ik een uitzondering, zoals in dit geval voor Lara van Klaveren
Titel: Op de schouders
Techniek: Aquarel en inkt op papier
Afmeting: 40x30cm
Jaartal: 2025
#watercolor #commission #ink #opdracht #aquarel #inkt #2cv #zee

MiNK Therapeutics Earnings: Cell Therapy Pioneer to Reveal Q2 Results and Pipeline Progress Clinical-stage biotech MiNK to discuss Q2 financials and iNKT cell therapy advances on August 14. Join key executives for complete corporate insights. Register now.

#INKT MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

www.stocktitan.net/news/INKT/mi-nk-therapeu...